Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.
Eighty-eight children with juvenile rheumatoid arthritis (JRA) who completed a double blind, randomized placebo controlled trial of oral gold were entered into an open label extension phase during which they received auranofin (AF) at a dosage of 0.15-0.2 mg/kg/day (9 mg/day maximum). Eleven (12.5%) patients completed 5 years of AF therapy; 77 (87.5%) did not. Fifteen (17%) of the 88 were in disease remission at the final visit. Mean duration of therapy for those who discontinued was 646 days. Parental/patient decision and insufficient therapeutic effect were the 2 most frequent reasons for early termination, followed by adverse effects. Though relatively well tolerated, AF provides adequate longterm management for only a small percentage of patients with JRA.
Giannini
E H
EH
Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229.
Barron
K S
KS
Spencer
C H
CH
Person
D A
DA
Baum
J
J
Bernstein
B H
BH
Kredich
D W
DW
Jacobs
J C
JC
Zemel
L S
LS
Gibbas
D
D
D000284:Administration, Oral; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001310:Auranofin / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006046:Gold / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D013997:Time Factors
D001310:Auranofin; D006046:Gold